Sugi Predict

Sugi Predict / Compounds / SCHEMBL10824415

SCHEMBL10824415

SCHEMBL10824415

CCOC(=O)CCn1cc(F)c(=O)[nH]c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 1.00
▸ KMT2A Q03164 5/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ CYP1A2 P05177 4/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ GRIA1 P42261 1/20 0.48
▸ GRIA2 P42262 1/20 0.48
▸ GRIA3 P42263 1/20 0.48
▸ GRIA4 P48058 1/20 0.48
▸ GRIK5 Q16478 1/20 0.48
▸ TNF P01375 3/20 0.47
▸ CREBBP Q92793 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CYP2C9 P11712 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ CYP2C19 P33261 3/20 0.41
▸ GAA P10253 1/20 0.41
▸ KAT2B Q92831 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12657435 0.92 LMNA (0.85) LMNAKMT2AMEN1CYP1A2KDM4E
SCHEMBL21695505 0.85 LMNA (0.74) LMNAKMT2ACREBBP
SCHEMBL28820753 0.83 LMNA (0.71) LMNAKMT2AMEN1CYP1A2KDM4E
SCHEMBL21695465 0.83 LMNA (0.71) LMNAKMT2ACYP1A2GRIA1GRIA2
SCHEMBL16574245 0.82 LMNA (0.69) LMNAKMT2AMEN1CYP1A2KDM4E
SCHEMBL8373971 0.80 LMNA (0.67) LMNAKMT2ACYP1A2KDM4EGRIA1
SCHEMBL28652297 0.80 LMNA (0.67) LMNAKMT2AMEN1CYP1A2KDM4E
SCHEMBL5479694 0.80 LMNA (0.67) LMNAKMT2AMEN1CYP1A2KDM4E
SCHEMBL19104595 0.79 LMNA (0.65) LMNAKMT2ACYP1A2KDM4EGRIA1
SCHEMBL14999666 0.78 LMNA (0.64) LMNAKMT2AMEN1CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-61060671-A — — None — — JP disclosed
US-20210230122-A1 5-FLUOROURACIL DERIVATIVES, PREPARATION METHODS AND USES THEREOF SHANGHAI ECUST BIOMEDICINE CO., LTD. (CN) 2021-07-29 — — US disclosed
US-20210085700-A1 TARGETED THERAPEUTICS MADRIGAL PHARMACEUTICALS, INC. 2021-03-25 — — US disclosed
US-10828315-B2 Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (US) 2020-11-10 — — US disclosed
CN-107698521-B Preparation and application of 5-fluorouracil substituted carboxylic acid derivative 上海华理生物医药股份有限公司 2020-08-07 — — CN disclosed
US-10722525-B2 Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (US) 2020-07-28 — — US disclosed
US-10232049-B2 Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (US) 2019-03-19 — — US disclosed
US-9956293-B2 Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (US) 2018-05-01 — — US disclosed
US-9956293-B2 Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (US) 2018-05-01 — — US disclosed
US-9702869-B2 Assays, antibodies, immunogens and compositions related to 5-FU DEFINED DIAGNOSTICS, LLC (US) 2017-07-11 — — US disclosed
US-20170049899-A1 TARGETED THERAPEUTICS LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2017-02-23 — — US disclosed
US-20170049899-A1 TARGETED THERAPEUTICS LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2017-02-23 — — US disclosed
US-20150139905-A1 TARGETED THERAPEUTICS MADRIGAL PHARMACEUTICALS, INC. 2015-05-21 — — US disclosed
US-20150139905-A1 TARGETED THERAPEUTICS MADRIGAL PHARMACEUTICALS, INC. 2015-05-21 — — US disclosed
WO-2015038649-A1 TARGETED THERAPEUTICS SYNTA PHARMACEUTICALS CORP. (US) 2015-03-19 — — WO disclosed
US-20150079612-A1 Assays, Antibodies, Immunogens and Compositions Related to 5-FU PHARMA CINQ, LLC 2015-03-19 — — US disclosed
US-20150079612-A1 Assays, Antibodies, Immunogens and Compositions Related to 5-FU PHARMA CINQ, LLC 2015-03-19 — — US disclosed
US-20140079636-A1 TARGETED THERAPEUTICS SYNTA PHARMACEUTICALS CORP. 2014-03-20 — — US disclosed
US-20140079636-A1 TARGETED THERAPEUTICS SYNTA PHARMACEUTICALS CORP. 2014-03-20 — — US disclosed
JP-S6160671-A 5-FLUOROURACIL DERIVATIVE CHISSO CORP 1986-03-28 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210085700-A1 TARGETED THERAPEUTICS CDC37, HSP90AB1, HSP90B1 LMNA 3127/4885KMT2A 4060/4885MEN1 3721/4885
US-20150139905-A1 TARGETED THERAPEUTICS CDC37, HSP90AB1, HSP90B1 LMNA 3127/4885KMT2A 4060/4885MEN1 3721/4885
US-20170049899-A1 TARGETED THERAPEUTICS CDC37, HSP90AB1, HSP90B1 LMNA 3127/4885KMT2A 4060/4885MEN1 3721/4885
US-10232049-B2 Targeted therapeutics CDC37, HSP90AB1, HSP90B1 LMNA 3127/4885KMT2A 4060/4885MEN1 3721/4885
US-10722525-B2 Targeted therapeutics CDC37, HSP90AB1, HSP90B1 LMNA 3127/4885KMT2A 4060/4885MEN1 3721/4885
US-10828315-B2 Targeted therapeutics CDC37, HSP90AB1, HSP90B1 LMNA 3127/4885KMT2A 4060/4885MEN1 3721/4885
US-20210230122-A1 5-FLUOROURACIL DERIVATIVES, PREPARATION METHODS AND USES THEREOF VEGFA, FLT4, FAU LMNA 3149/4885KMT2A 3566/4885MEN1 2255/4885
US-20150079612-A1 Assays, Antibodies, Immunogens and Compositions Related to 5-FU DPYD, MTHFD1, DHFR LMNA 4639/4885KMT2A 3902/4885MEN1 3350/4885
US-20140079636-A1 TARGETED THERAPEUTICS CDC37, HSP90AB1, HSP90B1 LMNA 3132/4885KMT2A 4056/4885MEN1 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.